PharmaShots | Incisive News in 3 Shots

Subscribe Now

Acute Hepatic Porphyria

Alnylam's Givlaari (givosiran) Receives EC's Approval for Acute Hepatic Porphyria in Adults and Adolescents

Alnylam's Givlaari (givosiran) Receives EC's Approval for Acute Hepatic Porphyria in Adults and Adolescents

March 4, 2020

Alnylam's Givlaari (givosiran) Receives the US FDA's Approval as the First Therapy for Acute Hepatic Porphyria

Alnylam's Givlaari (givosiran) Receives the US FDA's Approval as the First Therapy for Acute Hepatic Porphyria

November 21, 2019

Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

April 15, 2019

Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)

Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)

March 7, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us